Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 7 - Cervical Cancer Screening

  • Edited by Laurie J. Mckenzie, University of Texas MD Anderson Cancer Center, Houston, Denise R. Nebgen, University of Texas MD Anderson Cancer Center, Houston
  • Book:
    Caring for the Female Cancer Patient
    Published online:
    23 October 2024
    Print publication:
    17 October 2024, pp 107-116

  • Summary

    Though both preventable and curable, cervical cancer remains a leading cause of cancer-related deaths globally. It is generally understood that the overwhelming majority of cervical cancer cases are caused by persistent infection with high-risk human papillomavirus infection. In addition to other well-studied risk factors, it is well-established in the literature that there is an increased risk of progression from preinvasive disease to invasive cancer in women with immunosuppression, such as those living with human immunodeficiency virus (HIV) and those with cancer. In this chapter, we seek to summarize recommendations surrounding cervical cancer screening and treatment for women with who are immunosuppressed following cancer therapy. We review the use of cervical cytology and HPV testing and discuss their use in both patients of average and increased risk. We also review the American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines for treatment of preinvasive disease in immunocompromised patients.